Sun Pharma announces 5-year sustained efficacy & safety results for its psoriasis drug, ILUMYA
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis